NextCell Pharma AB

Company Profile

• Business description

  NextCell Pharma AB is a Swedish clinical-stage biotechnology company developing mesenchymal stromal cell (MSC)-based therapies for autoimmune and inflammatory diseases, with a primary focus on Type 1 Diabetes. Its key product candidate, ProTrans, is designed to preserve insulin-producing capacity in Type 1 Diabetes patients, while the company also operates Cellaviva, Scandinavia's private stem-cell bank, and QVance, which provides analytical and quality-control services for therapy medicinal products. It's operations are organized into three business areas: ProTrans (cell therapy development), Cellaviva (stem-cell banking), and QVance (ATMP analytical services). The company's activities are concentrated in Sweden and the Nordic region.

• Contact

  Karolinska Institutet Science Park
  Halsovagen 7
  Huddinge14157
  SWE

  T: +46 87355595

  https://www.nextcellpharma.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2026

  Employees

  24